Stemler, Jannik
Nacov, Julia A.
Sprute, Rosanne
Cornely, Oliver A.
Joest, Marcus
Becker, Sven
Klimek, Ludger
Funding for this research was provided by:
Universitätsklinikum Köln
Article History
Received: 22 January 2024
Accepted: 5 February 2024
First Online: 22 March 2024
Conflict of interest
: J. Stemler has received support for scientific projects from BMBF (Federal Ministry of Education and Research), Basilea Pharmaceuticals and Noscendo, honoraria for scientific presentations from AbbVie, Hikma, Gilead and Pfizer, consultancy fees from Alvea Vax, Gilead, Produkt&Markt GmbH, Micron Research as well as travel grants from the German Society for Infectious Diseases and the Meta-Alexander Foundation, outside the present work. J.A. Nacov has received honoraria for scientific lectures from Hikma, outside the present work. R. Sprute has received lecture honoraria from the Akademie für Infektionsmedizin e. V., Hikma and Pfizer as well as reimbursement of travel expenses from Pfizer, outside the scope of this work. O.A. Cornely reports grants or contracts from BMBF, Cidara, EU-DG RTD (101037867), F2G, Gilead, MedPace, MSD, Mundipharma, Octapharma, Pfizer, Scynexis; Consulting fees from Abbvie, AiCuris, Biocon, Cidara, Gilead, IQVIA, Janssen, Matinas, MedPace, Menarini, Moderna, Molecular Partners, MSG-ERC, Noxxon, Octapharma, Pfizer, PSI, Scynexis, Seres; Honoraria for lectures from Abbott, Abbvie, Al-Jazeera Pharmaceuticals/Hikma, Gilead, Grupo Biotoscana/United Medical/Knight, MedScape, MedUpdate, Merck/MSD, Noscendo, Pfizer, Shionogi, streamedup!; Payment for expert testimony from Cidara; Participation on a Data Safety Monitoring Board or Advisory Board from Boston Strategic Partners, Cidara, IQVIA, Janssen, MedPace, PSI, Pulmocide, Shionogi, The Prime Meridian Group; A patent at the German Patent and Trade Mark Office (DE 10 2021 113 007.7); Stocks from CoRe Consulting, EasyRadiology; Other interests from Wiley. M. Joest has received lecture fees or reimbursement of travel expenses from ALK Abello, Astra Zeneca, Bencard, Berlin Chemie, Boehringer Ingelheim, GSK, HAL Allergy. S. Becker has received lecture fees and consultancy fees from Allergy Therapeutics/Bencard, ALK-Abelló, Allergopharma, AstraZeneca, HAL Allergy, Viatris/Mylan, Novartis, GlaxoSmithKline (GSK), Sanofi, Thermofisher Scientific, Altamira AG, Auris medical, Smart Reporting, MSD. S. Becker has also received support for scientific projects from the BMBF (Federal Ministry of Education and Research). L. Klimek has received research grants from Allergy Therapeutics/Bencard, Great Britain/Germany; ALK-Abelló, Denmark; Allergopharma, Germany; Aimmune, USA; ASIT Biotech, Belgium; AstraZeneca, Sweden, Bionorica, Germany; Biomay, Austria, Boehringer Ingelheim, Germany, Circassia, USA; Chiesi, Italy; Cytos, Switzerland; Curalogic, Denmark; HAL, Netherlands; Lofarma, Italy; Menarini, Italy; Viatris/Mylan, USA; Novartis, Switzerland, Leti, Spain; ROXALL, Germany; GlaxoSmithKline (GSK), Great Britain; Sanofi, France; Stallergenes, France; Thermofisher, USA and/or has served on the speaker’s bureau or was consulting for the above mentioned pharmaceutical companies. He is the current President of German Society of Allergology AeDA, Vice-President of the European Academy for Allergy and Clinical Immunology (EAACI), Vice-President of German Academy for Allergy and Environmental Medicine and Editor-in-Chief of <i>Allergo Journal</i> and <i>Allergo Journal International</i>.